|
|
|
|
LEADER |
13025nma a2204513 u 4500 |
001 |
EB002048446 |
003 |
EBX01000000000000001192112 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
220822 ||| eng |
020 |
|
|
|a 9783036506319
|
020 |
|
|
|a books978-3-0365-0631-9
|
020 |
|
|
|a 9783036506302
|
100 |
1 |
|
|a Honecker, Friedemann
|
245 |
0 |
0 |
|a Marine Compounds and Cancer 2020
|h Elektronische Ressource
|
260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2021
|
300 |
|
|
|a 1 electronic resource (480 p.)
|
653 |
|
|
|a antioxidant
|
653 |
|
|
|a Lampetra morii
|
653 |
|
|
|a multidrug resistance
|
653 |
|
|
|a bromophenol
|
653 |
|
|
|a apoptosis-inducing activity
|
653 |
|
|
|a cell adhesion molecules
|
653 |
|
|
|a ABC transporter
|
653 |
|
|
|a p38α
|
653 |
|
|
|a Brevianamide
|
653 |
|
|
|a Nur77
|
653 |
|
|
|a humulane sesquiterpenoids
|
653 |
|
|
|a AD0157
|
653 |
|
|
|a p38/ERK
|
653 |
|
|
|a NF-κB signaling
|
653 |
|
|
|a plakortide
|
653 |
|
|
|a marine-derived drugs
|
653 |
|
|
|a fucoidan
|
653 |
|
|
|a tumor microenvironment
|
653 |
|
|
|a trabectedin
|
653 |
|
|
|a non-small cell lung carcinoma
|
653 |
|
|
|a FAU
|
653 |
|
|
|a antiproliferative activity
|
653 |
|
|
|a membrane permeabilization
|
653 |
|
|
|a fucoxanthin
|
653 |
|
|
|a angiogenesis inhibitor
|
653 |
|
|
|a tumor cell line
|
653 |
|
|
|a mitochondria
|
653 |
|
|
|a kalkitoxin
|
653 |
|
|
|a sponges
|
653 |
|
|
|a PEL
|
653 |
|
|
|a antitumour
|
653 |
|
|
|a human sarcoma cell line (HT1080 cells)
|
653 |
|
|
|a PI3K/Akt
|
653 |
|
|
|a cytoskeleton
|
653 |
|
|
|a Penicillium brevicompactum
|
653 |
|
|
|a endoperoxide
|
653 |
|
|
|a non-small cell lung cancer
|
653 |
|
|
|a marine antitumor agents
|
653 |
|
|
|a cembranoids
|
653 |
|
|
|a polyoxygenated steroids
|
653 |
|
|
|a sipholenol A
|
653 |
|
|
|a jaspine B
|
653 |
|
|
|a anthranilic acid
|
653 |
|
|
|a prostate cancer
|
653 |
|
|
|a SZ-685C
|
653 |
|
|
|a FBDD
|
653 |
|
|
|a A375 and HeLa cell lines
|
653 |
|
|
|a synergism
|
653 |
|
|
|a BEL-7402 cell
|
653 |
|
|
|a gliotoxin
|
653 |
|
|
|a natural marine compounds
|
653 |
|
|
|a hydroxylated lipids
|
653 |
|
|
|a brominated indoles
|
653 |
|
|
|a NF-κB
|
653 |
|
|
|a seaweed
|
653 |
|
|
|a phycocyanin
|
653 |
|
|
|a arrest of cell cycle
|
653 |
|
|
|a cancer
|
653 |
|
|
|a anticarcinogenic
|
653 |
|
|
|a epigonal organ
|
653 |
|
|
|a caspase cascade
|
653 |
|
|
|a lung cancer
|
653 |
|
|
|a antiangiogenic
|
653 |
|
|
|a programmed cell death-ligand 2
|
653 |
|
|
|a cancer genes
|
653 |
|
|
|a Lyngbya majuscula
|
653 |
|
|
|a MRP1/ABCC1
|
653 |
|
|
|a xyloketal B
|
653 |
|
|
|a antiangiogenesis
|
653 |
|
|
|a Penicillium paneum
|
653 |
|
|
|a cyclin D1
|
653 |
|
|
|a ET-743
|
653 |
|
|
|a chromatography
|
653 |
|
|
|a chemotherapy
|
653 |
|
|
|a anti-metastatic activity
|
653 |
|
|
|a sediment
|
653 |
|
|
|a invasion
|
653 |
|
|
|a novel inhibitor
|
653 |
|
|
|a cytotoxicity
|
653 |
|
|
|a proteomic
|
653 |
|
|
|a proliferation
|
653 |
|
|
|a pyrrolidinedione
|
653 |
|
|
|a TGF-β signaling
|
653 |
|
|
|a NSCLC
|
653 |
|
|
|a circulating tumor cells
|
653 |
|
|
|a Moorea producens
|
653 |
|
|
|a bioactive natural product
|
653 |
|
|
|a antiproliferative
|
653 |
|
|
|a HIF-1
|
653 |
|
|
|a cytotoxic activity
|
653 |
|
|
|a microalgae
|
653 |
|
|
|a mitochondria toxin
|
653 |
|
|
|a ansamycins
|
653 |
|
|
|a marine natural products
|
653 |
|
|
|a cystatin F
|
653 |
|
|
|a Porifera
|
653 |
|
|
|a c-JUN
|
653 |
|
|
|a n/a
|
653 |
|
|
|a gemcitabine
|
653 |
|
|
|a λ-carrageenan
|
653 |
|
|
|a natural products
|
653 |
|
|
|a anti-cancer
|
653 |
|
|
|a 3-alkylpyridinium polymers
|
653 |
|
|
|a 12-deacetyl-12-epi-scalaradial
|
653 |
|
|
|a fascaplysin
|
653 |
|
|
|a cell adhesion
|
653 |
|
|
|a inhibitor
|
653 |
|
|
|a autophagy inhibitors
|
653 |
|
|
|a neuroblastoma-rat sarcoma
|
653 |
|
|
|a ROS
|
653 |
|
|
|a energy stress
|
653 |
|
|
|a antifouling
|
653 |
|
|
|a glioblastoma
|
653 |
|
|
|a molecular docking
|
653 |
|
|
|a Streptomyces sp. SCSIO 11594
|
653 |
|
|
|a cell cycle arrest
|
653 |
|
|
|a poly(ADP-ribose)-polymerase inhibitor
|
653 |
|
|
|a benzo[a]pyrene
|
653 |
|
|
|a pachastrissamine
|
653 |
|
|
|a carotenoid
|
653 |
|
|
|a STAT3
|
653 |
|
|
|a AP-1
|
653 |
|
|
|a topoisomerase
|
653 |
|
|
|a chemoprevention
|
653 |
|
|
|a pheochromocytoma and paraganglioma
|
653 |
|
|
|a mechanisms of action
|
653 |
|
|
|a polysaccharides
|
653 |
|
|
|a selenium-containing polysaccharide-protein complex
|
653 |
|
|
|a CYP1A1
|
653 |
|
|
|a DNA minor groove binder
|
653 |
|
|
|a αO-conotoxin GeXIVA
|
653 |
|
|
|a SNORA62
|
653 |
|
|
|a chemosensitization
|
653 |
|
|
|a c-Met
|
653 |
|
|
|a marine sponges
|
653 |
|
|
|a anticancer immunity
|
653 |
|
|
|a β1-integrin
|
653 |
|
|
|a EMT
|
653 |
|
|
|a Topo I inhibitor
|
653 |
|
|
|a drug discovery
|
653 |
|
|
|a leukemia
|
653 |
|
|
|a marine drug
|
653 |
|
|
|a antibacterial
|
653 |
|
|
|a phlorotannins
|
653 |
|
|
|a p38
|
653 |
|
|
|a antitumor activities
|
653 |
|
|
|a puupehenones
|
653 |
|
|
|a cancer progression
|
653 |
|
|
|a fumigaclavine C
|
653 |
|
|
|a fatty acid 2-hydroxylase
|
653 |
|
|
|a manzamine A
|
653 |
|
|
|a CHOP
|
653 |
|
|
|a gene expression
|
653 |
|
|
|a marine organisms
|
653 |
|
|
|a breast cancer cells
|
653 |
|
|
|a sea anemone
|
653 |
|
|
|a anti-proliferation
|
653 |
|
|
|a heparanase
|
653 |
|
|
|a marine mollusc
|
653 |
|
|
|a Leathesia nana
|
653 |
|
|
|a soft tissue sarcoma
|
653 |
|
|
|a divergolides
|
653 |
|
|
|a p65
|
653 |
|
|
|a Cantabrian Sea-derived actinobacteria
|
653 |
|
|
|a itampolin A
|
653 |
|
|
|a soft coral
|
653 |
|
|
|a Ecklonia cava
|
653 |
|
|
|a programmed cell death
|
653 |
|
|
|a hypoxia
|
653 |
|
|
|a Marthasterias glacialis L.
|
653 |
|
|
|a hepatocellular carcinoma
|
653 |
|
|
|a cancer preventive
|
653 |
|
|
|a autophagy inducers
|
653 |
|
|
|a mitochondrial pathway
|
653 |
|
|
|a epithelial-mesenchymal transition
|
653 |
|
|
|a kunitz type inhibitor
|
653 |
|
|
|a glycosaminoglycans
|
653 |
|
|
|a safety
|
653 |
|
|
|a non-small cell lung cancer (NSCLC)
|
653 |
|
|
|a marine metabolites
|
653 |
|
|
|a TNFα
|
653 |
|
|
|a dibromotyrosine
|
653 |
|
|
|a carotenoids
|
653 |
|
|
|a cyclin-dependent kinase
|
653 |
|
|
|a cisplatin
|
653 |
|
|
|a nicotinic acetylcholine receptor
|
653 |
|
|
|a Sepia ink polysaccharides
|
653 |
|
|
|a pollution
|
653 |
|
|
|a MAPK/ERK pathway
|
653 |
|
|
|a HER2
|
653 |
|
|
|a small cell lung cancer
|
653 |
|
|
|a MCP-1
|
653 |
|
|
|a Haliclona gracilis
|
653 |
|
|
|a anti-angiogenic
|
653 |
|
|
|a thalassiolin B
|
653 |
|
|
|a clinical trials
|
653 |
|
|
|a bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane (BDDPM)
|
653 |
|
|
|a Isofistularin
|
653 |
|
|
|a gorgonian
|
653 |
|
|
|a antitumor
|
653 |
|
|
|a molecular oncology
|
653 |
|
|
|a human lung cancer
|
653 |
|
|
|a elisidepsin
|
653 |
|
|
|a P2X7 receptor
|
653 |
|
|
|a Akt
|
653 |
|
|
|a RGD motif
|
653 |
|
|
|a lung metastasis
|
653 |
|
|
|a uveal melanoma
|
653 |
|
|
|a secondary metabolites
|
653 |
|
|
|a bioanalysis
|
653 |
|
|
|a azoxymethane
|
653 |
|
|
|a reactive oxygen species
|
653 |
|
|
|a colorectal cancer
|
653 |
|
|
|a nanoparticle
|
653 |
|
|
|a chemical conjugation
|
653 |
|
|
|a naphthopyrones
|
653 |
|
|
|a human normal diploid fibroblast (TIG-1 cells)
|
653 |
|
|
|a sphingosine kinase inhibitor
|
653 |
|
|
|a TRPM7
|
653 |
|
|
|a depolymerisation
|
653 |
|
|
|a multi-drug resistant leukemia
|
653 |
|
|
|a heparan sulphate
|
653 |
|
|
|a therapeutic compounds
|
653 |
|
|
|a carcinoembryonic antigen
|
653 |
|
|
|a anti-proliferative
|
653 |
|
|
|a Antibody Drug Conjugates (ADCs)
|
653 |
|
|
|a araguspongine C
|
653 |
|
|
|a triterpene glycosides
|
653 |
|
|
|a melanoma
|
653 |
|
|
|a integrin β1
|
653 |
|
|
|a LS-1
|
653 |
|
|
|a low molecular weight fucoidan extract
|
653 |
|
|
|a molecular mechanisms
|
653 |
|
|
|a autophagy
|
653 |
|
|
|a migration
|
653 |
|
|
|a anticancer agent
|
653 |
|
|
|a Mycalin A
|
653 |
|
|
|a Micromonospora
|
653 |
|
|
|a evolution
|
653 |
|
|
|a molecular modeling
|
653 |
|
|
|a Tilapia piscidin 4 (TP4)
|
653 |
|
|
|a HeLa cells
|
653 |
|
|
|a sea cucumbers
|
653 |
|
|
|a natural product
|
653 |
|
|
|a targeted therapy
|
653 |
|
|
|a Medicine and Nursing / bicssc
|
653 |
|
|
|a Aspergillus
|
653 |
|
|
|a BCRP/ABCG2
|
653 |
|
|
|a cytokine release
|
653 |
|
|
|a C15 acetogenins
|
653 |
|
|
|a polyphenols
|
653 |
|
|
|a FAK
|
653 |
|
|
|a mitochondrial dysfunction
|
653 |
|
|
|a sinulariolide
|
653 |
|
|
|a anti-angiogenesis
|
653 |
|
|
|a pazopanib
|
653 |
|
|
|a terpenes
|
653 |
|
|
|a marangucyclines
|
653 |
|
|
|a Thalassia testudinum
|
653 |
|
|
|a α9-nicotinic acetylcholine receptors (nAChRs)
|
653 |
|
|
|a angiogenesis
|
653 |
|
|
|a cell cycle
|
653 |
|
|
|a dieckol
|
653 |
|
|
|a inflammation
|
653 |
|
|
|a Sarcophyton ehrenbergi
|
653 |
|
|
|a VEGF
|
653 |
|
|
|a tetracenomycin X
|
653 |
|
|
|a actinomycin
|
653 |
|
|
|a Cancer
|
653 |
|
|
|a chimera
|
653 |
|
|
|a glucocorticoid receptor
|
653 |
|
|
|a synthetic analogues
|
653 |
|
|
|a fatty acids
|
653 |
|
|
|a carbocyclic analogue
|
653 |
|
|
|a HSP90
|
653 |
|
|
|a Mycochromenic acid derivative
|
653 |
|
|
|a deep-sea
|
653 |
|
|
|a cell migration
|
653 |
|
|
|a N-Ras
|
653 |
|
|
|a nicotine
|
653 |
|
|
|a preclinical
|
653 |
|
|
|a hypoxia-inducible factor-1
|
653 |
|
|
|a anticoagulation
|
653 |
|
|
|a Jurkat
|
653 |
|
|
|a shrimp
|
653 |
|
|
|a pseudopterosin
|
653 |
|
|
|a A549 cells
|
653 |
|
|
|a Caribbean sponge
|
653 |
|
|
|a anticancer
|
653 |
|
|
|a JNK1/2
|
653 |
|
|
|a antitumoral
|
653 |
|
|
|a mangrove-derived actinomycete
|
653 |
|
|
|a marine fungus
|
653 |
|
|
|a anticoagulant
|
653 |
|
|
|a ribosomal protein genes
|
653 |
|
|
|a macrolide
|
653 |
|
|
|a marine biotechnology
|
653 |
|
|
|a anticancer activity
|
653 |
|
|
|a apoptosis
|
653 |
|
|
|a approved antitumor agents
|
653 |
|
|
|a hippuristanol
|
653 |
|
|
|a nonfunctioning pituitary adenomas
|
653 |
|
|
|a breast cancer
|
653 |
|
|
|a proteasomal degradation
|
653 |
|
|
|a camptothecin
|
653 |
|
|
|a sponge
|
653 |
|
|
|a endophytic fungus
|
653 |
|
|
|a virtual screening
|
653 |
|
|
|a palmitic acid
|
653 |
|
|
|a Aeroplysinin
|
653 |
|
|
|a cystatin superfamily
|
653 |
|
|
|a RPS30
|
653 |
|
|
|a porifera/sponge
|
653 |
|
|
|a snoRNA
|
653 |
|
|
|a paulomycins
|
653 |
|
|
|a cooperative binding
|
653 |
|
|
|a metastasis
|
653 |
|
|
|a Ulva fasciata
|
653 |
|
|
|a programmed cell death-ligand 1
|
653 |
|
|
|a tumor-associated macrophages
|
653 |
|
|
|a lipid rafts
|
653 |
|
|
|a marine drugs
|
653 |
|
|
|a oxidative stress
|
653 |
|
|
|a IL-6
|
653 |
|
|
|a Antimicrobial peptide (AMP)
|
653 |
|
|
|a low toxic
|
653 |
|
|
|a isatin
|
653 |
|
|
|a Leptogorgia
|
653 |
|
|
|a bonnethead shark
|
653 |
|
|
|a osteosarcoma
|
653 |
|
|
|a endothelial cells
|
653 |
|
|
|a hybridization
|
653 |
|
|
|a P-gp/ABCB1
|
653 |
|
|
|a ER-stress
|
653 |
|
|
|a in vivo model
|
653 |
|
|
|a SNU-C5/5-FU
|
653 |
|
|
|a phase I
|
653 |
|
|
|a signal transduction
|
653 |
|
|
|a plitidepsin
|
653 |
|
|
|a adriamycin resistance
|
653 |
|
|
|a marine compound
|
653 |
|
|
|a chemopreventive
|
653 |
|
|
|a buccal gland
|
700 |
1 |
|
|a Dyshlovoy, Sergey A.
|
700 |
1 |
|
|a Honecker, Friedemann
|
700 |
1 |
|
|a Dyshlovoy, Sergey A.
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
028 |
5 |
0 |
|a 10.3390/books978-3-0365-0631-9
|
856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/3853
|7 0
|x Verlag
|3 Volltext
|
856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/76418
|z DOAB: description of the publication
|
082 |
0 |
|
|a 610
|
082 |
0 |
|
|a 333
|
082 |
0 |
|
|a 380
|
082 |
0 |
|
|a 363
|
082 |
0 |
|
|a 576
|
082 |
0 |
|
|a 304
|
082 |
0 |
|
|a 140
|
082 |
0 |
|
|a 700
|
082 |
0 |
|
|a 600
|
520 |
|
|
|a The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.
|